BACKGROUND: Alcohol abuse has been associated with HIV/AIDS progression, but the effects of HIV infection and treatment on alcohol exposure have not been explored to date. This pilot study examines the relationship of untreated HIV infection to blood alcohol concentrations (BAC) relative to BAC after initiation of antiretroviral therapy (ART). METHODS:Fifteen volunteers with untreated HIV/AIDS participated in 2 sets ofalcohol or alcohol placebo administration studies before and after initiation of ART. Oral alcohol (1 g/kg) or alcohol placebo was administered, participants were followed for pharmacokinetics, subjective responses, and cognitive effects over 8 hours. After initial alcohol studies, the ART regimen selected by participant clinicians was instituted. Observed ART dosing took place for at least 2 weeks. Participants then returned for a second set of alcohol/placebo administration studies while on ART. RESULTS: Participants had significantly higher BAC (P < 0.001) before ART than after ART administration. Alcohol area under the curve was significantly higher in untreated HIV disease (P = 0.011) with significantly higher C(max) (P = 0.015) and C(min) (P = 0.05). The elimination rate was not different between pre-ART and post-ART conditions. Despite declines in BAC after ART initiation, no differences in subjective responses were observed with alcohol administration. CONCLUSIONS: Untreated HIV infection is associated with risk for higher BAC than that observed after ART. These findings indicate that patients with untreated HIV disease who ingest alcohol are at greater risk for alcohol associated adverse events and toxicities and underscores the need for simultaneous treatment of alcohol use disorders and HIV in patients with co-occurring conditions.
RCT Entities:
BACKGROUND:Alcohol abuse has been associated with HIV/AIDS progression, but the effects of HIV infection and treatment on alcohol exposure have not been explored to date. This pilot study examines the relationship of untreated HIV infection to blood alcohol concentrations (BAC) relative to BAC after initiation of antiretroviral therapy (ART). METHODS: Fifteen volunteers with untreated HIV/AIDS participated in 2 sets of alcohol or alcohol placebo administration studies before and after initiation of ART. Oral alcohol (1 g/kg) or alcohol placebo was administered, participants were followed for pharmacokinetics, subjective responses, and cognitive effects over 8 hours. After initial alcohol studies, the ART regimen selected by participant clinicians was instituted. Observed ART dosing took place for at least 2 weeks. Participants then returned for a second set of alcohol/placebo administration studies while on ART. RESULTS:Participants had significantly higher BAC (P < 0.001) before ART than after ART administration. Alcohol area under the curve was significantly higher in untreated HIV disease (P = 0.011) with significantly higher C(max) (P = 0.015) and C(min) (P = 0.05). The elimination rate was not different between pre-ART and post-ART conditions. Despite declines in BAC after ART initiation, no differences in subjective responses were observed with alcohol administration. CONCLUSIONS: Untreated HIV infection is associated with risk for higher BAC than that observed after ART. These findings indicate that patients with untreated HIV disease who ingest alcohol are at greater risk for alcohol associated adverse events and toxicities and underscores the need for simultaneous treatment of alcohol use disorders and HIV in patients with co-occurring conditions.
Authors: Sumathi Sankaran; Michael D George; Elizabeth Reay; Moraima Guadalupe; Jason Flamm; Thomas Prindiville; Satya Dandekar Journal: J Virol Date: 2007-10-24 Impact factor: 5.103
Authors: R S Braithwaite; J Conigliaro; M S Roberts; S Shechter; A Schaefer; K McGinnis; M C Rodriguez; L Rabeneck; K Bryant; A C Justice Journal: AIDS Care Date: 2007-04
Authors: Amanda J Chase; Ahmad R Sedaghat; Jennifer R German; Lucio Gama; M Christine Zink; Janice E Clements; Robert F Siliciano Journal: J Virol Date: 2007-09-12 Impact factor: 5.103
Authors: H-J Epple; T Schneider; H Troeger; D Kunkel; K Allers; V Moos; M Amasheh; C Loddenkemper; M Fromm; M Zeitz; J-D Schulzke Journal: Gut Date: 2008-10-20 Impact factor: 23.059
Authors: Petronela Ancuta; Anupa Kamat; Kevin J Kunstman; Eun-Young Kim; Patrick Autissier; Alysse Wurcel; Tauheed Zaman; David Stone; Megan Mefford; Susan Morgello; Elyse J Singer; Steven M Wolinsky; Dana Gabuzda Journal: PLoS One Date: 2008-06-25 Impact factor: 3.240
Authors: E Jennifer Edelman; Stephen A Maisto; Nathan B Hansen; Christopher J Cutter; James Dziura; Lynn E Fiellin; Patrick G O'Connor; Roger Bedimo; Cynthia Gibert; Vincent C Marconi; David Rimland; Maria C Rodriguez-Barradas; Michael S Simberkoff; Amy C Justice; Kendall J Bryant; David A Fiellin Journal: Contemp Clin Trials Date: 2016-11-20 Impact factor: 2.226
Authors: Valerie A Gruber; Petrie M Rainey; Paula J Lum; George W Beatty; Francesca T Aweeka; Elinore F McCance-Katz Journal: J Int Assoc Provid AIDS Care Date: 2013-07-23
Authors: Kirsha S Gordon; E Jennifer Edelman; Amy C Justice; David A Fiellin; Kathleen Akgün; Stephen Crystal; Mona Duggal; Joseph L Goulet; David Rimland; Kendall J Bryant Journal: AIDS Behav Date: 2017-05
Authors: Amy C Justice; Kathleen A McGinnis; Janet P Tate; R Scott Braithwaite; Kendall J Bryant; Robert L Cook; E Jennifer Edelman; Lynn E Fiellin; Matthew S Freiberg; Adam J Gordon; Kevin L Kraemer; Brandon D L Marshall; Emily C Williams; David A Fiellin Journal: Drug Alcohol Depend Date: 2016-01-29 Impact factor: 4.492
Authors: Kathleen A McGinnis; Janet P Tate; Emily C Williams; Melissa Skanderson; Kendall J Bryant; Adam J Gordon; Kevin L Kraemer; Stephen A Maisto; Steven Crystal; David A Fiellin; Amy C Justice Journal: Drug Alcohol Depend Date: 2016-09-22 Impact factor: 4.492
Authors: Emily C Williams; Judith A Hahn; Richard Saitz; Kendall Bryant; Marlene C Lira; Jeffrey H Samet Journal: Alcohol Clin Exp Res Date: 2016-09-22 Impact factor: 3.455